(4-[(S)-2-ACETYLAMINO-2-[(S)-1-(3-CARBAMOYL-4-CYCLOHEXYLMETHOXYPHENYL)-ETHYLCARBAMOYL]-ETHYL]-BENZYL)-PHOSPHONIC-ACID
Compound with spectra: 1 NMR
![(4-[(S)-2-ACETYLAMINO-2-[(S)-1-(3-CARBAMOYL-4-CYCLOHEXYLMETHOXYPHENYL)-ETHYLCARBAMOYL]-ETHYL]-BENZYL)-PHOSPHONIC-ACID](/api/compound/EtaBZiVDQ4w.png?ph=true&h=300&w=458 "(4-[(S)-2-ACETYLAMINO-2-[(S)-1-(3-CARBAMOYL-4-CYCLOHEXYLMETHOXYPHENYL)-ETHYLCARBAMOYL]-ETHYL]-BENZYL)-PHOSPHONIC-ACID")
| SpectraBase Compound ID | EtaBZiVDQ4w |
|---|---|
| InChI | InChI=1S/C28H38N3O7P/c1-18(23-12-13-26(24(15-23)27(29)33)38-16-21-6-4-3-5-7-21)30-28(34)25(31-19(2)32)14-20-8-10-22(11-9-20)17-39(35,36)37/h8-13,15,18,21,25H,3-7,14,16-17H2,1-2H3,(H2,29,33)(H,30,34)(H,31,32)(H2,35,36,37)/t18-,25-/m0/s1 |
| InChIKey | VAUMRIIUBCMOSB-BVZFJXPGSA-N |
| Mol Weight | 559.6 g/mol |
| Molecular Formula | C28H38N3O7P |
| Exact Mass | 559.244738 g/mol |
| Enantiomer InChIKey | VAUMRIIUBCMOSB-IQGLISFBSA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | DMSO-D6 |
H-GLU-TYR-[SO2C6H4(4-COOH)]-LEU-OBZL
(2S)-2-(-2,3-Dimethoxyphenyl)carbonylamino-N-(2,3-dimethoxybenzyl)-3-phenylethyl amide
TYR-(1-S,2-R)-ACHC-PHE-PARA-F-PHE-NH2
(3S,6R,10R,13E,16R)-10-(3-chloro-4-methoxy-benzyl)-16-[(E)-cinnamyl]-3-isobutyl-6-methyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-diquinone
Hexapeptide boc-leu-tyr(bzl)-leu-val-cys(set)-gly-04
BOC-PHE-CYS((O)ME)-CYS(TRT)-OME
ARTERININ-B
[(2S),N(1S)]-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxy-N-(2-hydroxy-1-phenylethyl)propanamide
6-chloro-N-[1-(3,4-dimethylphenyl)ethyl]-2-oxo-2H-chromene-3-carboxamide
2-[1,3-bis(oxidanylidene)isoindol-2-yl]-N-tert-butyl-3-(4-nitrophenyl)propanamide
| Title | Journal or Book | Year |
|---|---|---|
| X-ray Structure of Citrate Bound to Src SH2 Leads to a High-Affinity, Bone-Targeted Src SH2 Inhibitor | Journal of Medicinal Chemistry | 2001 |